prevalence of thrombophilic factors in pregnant women with subjectively oligohydraminos during the gestational age of 18- 27 weeks

To study the prevalence of Factor V Leiden [FVL], prothrombin gene mutation G20210A [F II] and methylenetetrahydrofolate reductase C677T [MTHFR] in pregnant women with subjectively diagnosed oligohydraminos during the gestational age from 18-27 weeks. A case-control study was conducted at the Jordan University Hospital and Farah Hospital Amman, Jordan during the period of 2006-2009. 100 pregnant women with oligohydraminos have been compared to 96 normal healthy childbearing age women. All subjects were investigated for the 3 genetically related thrombophilic factors. Prothrombin gene mutation G20210A [F II] in pregnant women with oligohydraminos was higher 7.0% Vs 0% in the control group with a P-value of 0.008. Factor V Leiden [FVL] was also higher among pregnant women with subjectively oligohydraminos, 23.0% Vs 13.5% among the control group, but it did not reach statistical significance, P-value was 0.087. Methylenetetrahydrofolate Reductase C677T [MTHFR] was 52% among the pregnant women with subjectively oligohydraminos versus 55.2% in the control group: P-value was 0.653 as shown in Table [2]. As compared to the control group, Factor II G20210A was significantly higher among the pregnant women with subjectively oligohydraminos while FVL was also higher among this group, but it did not reach statistical significance. MTHFR was not higher among this group of pregnant women

Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan

To study the frequency of Factor V Leiden [FVL], prothrombin gene mutation G20210A and methylenetetrahydrofolate reductase C677T in patients with acute pulmonary embolism [PE]; and to investigate whether these factors are more frequent in patients who have no obvious risk factors for venous thrombo-embolism compared to those with obvious risk factors. A case-control study conducted at Jordan University Hospital, Amman, Jordan during the period 2005-2007. Compared 92 patients with acute PE to 99 normal subjects. All subjects were investigated for the 3 genetically related thrombophilic factors. The frequency of these factors in patients were 22/92 [23.9%] FVL, 3/92 [3.3%] Factor II [FII] and 48/92 [52.2%] methylenetetrahydrofolate reductase [MTHFR]. In the control group, FVL was 12/99 [12.1%], FII 0/99 [0%], and 53/99 [53.5%] MTHFR. There was a statistically significant difference between patients and controls for FVL [p=0.03], but no statistical significance for FII [p=0.10] and MTHFR [p=0.85]. In patients with no obvious risk factors, the frequency of these factors were 8/29 [27.6%] FVL, 2/29 [6.9%] FII, and 14/29 [48.3%] for MTHFR compared to patients with obvious risk factors 14/63 [22.2%] for FVL, 1/63 [1.6%] FII, and 33/63 [52.3%] MTHFR. The FVL is statistically more frequent in patients with PE compared to the control group, and the frequency of FVL, FII, and MTHFR is not significantly higher in patients with acute PE who have no obvious risk factors compared to those with obvious risk factors

Methylenetetrahydrofolate reductase [MTHFR] genotype association with the risk of chronic myelogenous leukemia

The metabolism of folate is essential in DNA synthesis, and polymorphisms of genes involved in this metabolism have been implicated in many types of cancer. One such gene is the Methylenetetrahydrofolate Reductase [MTHFR] gene, which encodes an enzyme that converts folate to a methyl donor used for DNA methylation. In this report, we studied the association between the different genotypes of the two most common MTHFR polymophisms, C677T and A1298C, and the risk of Chronic Myelogenous Leukemia [CML]. For this purpose, 149 of previously diagnosed CML patients and 170 normal controls were examined using PCR followed by Restriction Fragment Length Polymorphism [RFLP]. Results showed that the frequency of the C677T TT homozygous mutant genotype in patients with CML was significantly higher compared to controls [OR - 2.84, 95% CI: 1.24-6.50, .P-value - 0.014]. No such association was shown for the heterozygous C677T CT genotype [OR = 1.52, 95% CI: 0.95-2.41, P-value - 0.081]. As for the A1298C genotypes, a statistically significant higher frequency of the mutant homozygous genotype 1298CC was also detected in CML patients compared to the control group [OR - 2.18, 95% CI: 1.01-4.69, P-value - 0.046]. No such statistical significance was demonstrable for the heterozygote genotype 1298AC [OR = 1.08, 95% CI: 0.68-1.73, P-value = 0.743]. This is the first report to suggest that both mutated MTHFR genotypes, specifically the homozygous 677TT and 1298CC polymorphisms, can be associated with a higher risk of developing CML

use of mammography among Jordanian women: findings from the behavioral risk factor surveillance system 2007

This study aims to provide a national estimate of the rate of utilization of mammography among Jordanian women aged 35 years and above and the impact of the different variables affecting this utilization. Data were derived from the Risk Factor Surveillance Survey conducted in 2007, focusing on all women aged 35 years and above with a total of 1161. Dependant variables were mammography utilization, while Predictor variables were; age, marital status, education, income, medical insurance, medical service providers, residency and health status as perceived by the respondents. Appropriate analysis was used to assess the relationships between these variables. Only 12.5% had mammography. Utilization increased with increasing age, level of education and with the higher income level. Non-insured and those who obtained medical service through the private sector had more utilization. Women in good health who are residing in the middle part of the country showed higher rates of mammography. This national study has demonstrated underutilization of mammography. It provides basic data for future studies. Initiating a national program for screening helps to find out measures to facilitate utilization of mammography as easy access and reduced cost. Improvement of income, education level and insurance will positively influence mammography utilization